

# **2019 Future of Epidermolysis Bullosa R&D Pipeline Drugs and Companies- Analysis of Global Epidermolysis Bullosa Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments**

<https://marketpublishers.com/r/2D6F96EEE35EN.html>

Date: January 2019

Pages: 90

Price: US\$ 2,199.00 (Single User License)

ID: 2D6F96EEE35EN

## **Abstracts**

The global demand for Epidermolysis Bullosa treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Epidermolysis Bullosa pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Epidermolysis Bullosa pipeline companies from advancing their products into Phase 3 or Phase 4.

### **Epidermolysis Bullosa Report Description**

The H1 2019 pipeline review report on Epidermolysis Bullosa pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Epidermolysis Bullosa pipeline compounds.

The Epidermolysis Bullosa pipeline guide presents information on all active drugs currently being developed for Epidermolysis Bullosa. The research work provides details of active therapeutic candidates in different phases including discovery,

research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Epidermolysis Bullosa pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Epidermolysis Bullosa drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Epidermolysis Bullosa product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Epidermolysis Bullosa pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Epidermolysis Bullosa pipeline report includes

An overview of Epidermolysis Bullosa disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of pipeline compounds

Company wise list of pipeline compounds

Mechanism of Action wise pipeline compounds

For each pipeline product, the following details are provided-

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials

## **REASONS TO BUY**

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Epidermolysis Bullosa pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Epidermolysis Bullosa pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into the market through in-depth strategic analysis review

Know the list of companies participating in global Epidermolysis Bullosa pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and

company

The report will be delivered in 2 working days.

## Contents

### **1. TABLE OF CONTENTS**

- 1.1 List of Tables
- 1.2 List of Figures

### **2. GLOBAL EPIDERMOLYSIS BULLOSA PIPELINE OVERVIEW**

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Report Guide and Research Methodology

### **3. EXECUTIVE SUMMARY**

- 3.1 Epidermolysis Bullosa Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
- 3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
- 3.4 Companies involved in Epidermolysis Bullosa pipeline, H1- 2019
- 3.5 Mechanism of Action wise Epidermolysis Bullosa Pipeline Candidates

### **4. ABEONA THERAPEUTICS INC EPIDERMOLYSIS BULLOSA PIPELINE DETAILS**

- 4.1 Abeona Therapeutics Inc Business Profile
- 4.2 Abeona Therapeutics Inc Epidermolysis Bullosa Drug Details
  - 4.2.1 Drug Snapshot
    - 4.2.1.1 Originator
    - 4.2.1.2 Collaborator/Co-Developer
    - 4.2.1.3 Route of Administration
    - 4.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 4.2.1.5 Area
    - 4.2.1.6 Type of Molecular Entity
- 4.3 Current Status
- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

## **5. AEGLE THERAPEUTICS CORP EPIDERMOLYSIS BULLOSA PIPELINE DETAILS**

- 5.1 Aegle Therapeutics Corp Business Profile
- 5.2 Aegle Therapeutics Corp Epidermolysis Bullosa Drug Details
  - 5.2.1 Drug Snapshot
    - 5.2.1.1 Originator
    - 5.2.1.2 Collaborator/Co-Developer
    - 5.2.1.3 Route of Administration
    - 5.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 5.2.1.5 Area
    - 5.2.1.6 Type of Molecular Entity
- 5.3 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

## **6. AMRYT PHARMA PLC EPIDERMOLYSIS BULLOSA PIPELINE DETAILS**

- 6.1 Amryt Pharma plc Business Profile
- 6.2 Amryt Pharma plc Epidermolysis Bullosa Drug Details
  - 6.2.1 Drug Snapshot
    - 6.2.1.1 Originator
    - 6.2.1.2 Collaborator/Co-Developer
    - 6.2.1.3 Route of Administration
    - 6.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 6.2.1.5 Area
    - 6.2.1.6 Type of Molecular Entity
- 6.3 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

## **7. ANTEROGEN CO LTD EPIDERMOLYSIS BULLOSA PIPELINE DETAILS**

- 7.1 Anterogen Co Ltd Business Profile
- 7.2 Anterogen Co Ltd Epidermolysis Bullosa Drug Details
  - 7.2.1 Drug Snapshot

- 7.2.1.1 Originator
- 7.2.1.2 Collaborator/Co-Developer
- 7.2.1.3 Route of Administration
- 7.2.1.4 Orphan Drug/Fast Track/Special Designation
- 7.2.1.5 Area
- 7.2.1.6 Type of Molecular Entity
- 7.3 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

## **8. AZITRA INC EPIDERMOLYSIS BULLOSA PIPELINE DETAILS**

- 8.1 Azitra Inc Business Profile
- 8.2 Azitra Inc Epidermolysis Bullosa Drug Details
  - 8.2.1 Drug Snapshot
    - 8.2.1.1 Originator
    - 8.2.1.2 Collaborator/Co-Developer
    - 8.2.1.3 Route of Administration
    - 8.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 8.2.1.5 Area
    - 8.2.1.6 Type of Molecular Entity
- 8.3 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

## **9. BERG LLC EPIDERMOLYSIS BULLOSA PIPELINE DETAILS**

- 9.1 Berg LLC Business Profile
- 9.2 Berg LLC Epidermolysis Bullosa Drug Details
  - 9.2.1 Drug Snapshot
    - 9.2.1.1 Originator
    - 9.2.1.2 Collaborator/Co-Developer
    - 9.2.1.3 Route of Administration
    - 9.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 9.2.1.5 Area

- 9.2.1.6 Type of Molecular Entity
- 9.3 Current Status
- 9.4 Drug Overview
- 9.5 Drug Mechanism of Action
- 9.6 Clinical/Pre-clinical Trial Details
- 9.7 Latest Drug Developments

## **10. BRIDGEBIO INC EPIDERMOLYSIS BULLOSA PIPELINE DETAILS**

- 10.1 BridgeBio Inc Business Profile
- 10.2 BridgeBio Inc Epidermolysis Bullosa Drug Details
  - 10.2.1 Drug Snapshot
    - 10.2.1.1 Originator
    - 10.2.1.2 Collaborator/Co-Developer
    - 10.2.1.3 Route of Administration
    - 10.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 10.2.1.5 Area
    - 10.2.1.6 Type of Molecular Entity
- 10.3 Current Status
- 10.4 Drug Overview
- 10.5 Drug Mechanism of Action
- 10.6 Clinical/Pre-clinical Trial Details
- 10.7 Latest Drug Developments

## **11. CONSTANT PHARMACEUTICALS LLC EPIDERMOLYSIS BULLOSA PIPELINE DETAILS**

- 11.1 Constant Pharmaceuticals LLC Business Profile
- 11.2 Constant Pharmaceuticals LLC Epidermolysis Bullosa Drug Details
  - 11.2.1 Drug Snapshot
    - 11.2.1.1 Originator
    - 11.2.1.2 Collaborator/Co-Developer
    - 11.2.1.3 Route of Administration
    - 11.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 11.2.1.5 Area
    - 11.2.1.6 Type of Molecular Entity
- 11.3 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action



11.6 Clinical/Pre-clinical Trial Details

11.7 Latest Drug Developments

## **12. CSL LTD EPIDERMOLYSIS BULLOSA PIPELINE DETAILS**

12.1 CSL Ltd Business Profile

12.2 CSL Ltd Epidermolysis Bullosa Drug Details

12.2.1 Drug Snapshot

12.2.1.1 Originator

12.2.1.2 Collaborator/Co-Developer

12.2.1.3 Route of Administration

12.2.1.4 Orphan Drug/Fast Track/Special Designation

12.2.1.5 Area

12.2.1.6 Type of Molecular Entity

12.3 Current Status

12.4 Drug Overview

12.5 Drug Mechanism of Action

12.6 Clinical/Pre-clinical Trial Details

12.7 Latest Drug Developments

## **13. EMBER THERAPEUTICS INC EPIDERMOLYSIS BULLOSA PIPELINE DETAILS**

13.1 Ember Therapeutics Inc Business Profile

13.2 Ember Therapeutics Inc Epidermolysis Bullosa Drug Details

13.2.1 Drug Snapshot

13.2.1.1 Originator

13.2.1.2 Collaborator/Co-Developer

13.2.1.3 Route of Administration

13.2.1.4 Orphan Drug/Fast Track/Special Designation

13.2.1.5 Area

13.2.1.6 Type of Molecular Entity

13.3 Current Status

13.4 Drug Overview

13.5 Drug Mechanism of Action

13.6 Clinical/Pre-clinical Trial Details

13.7 Latest Drug Developments

## **14. FIBROCELL SCIENCE INC EPIDERMOLYSIS BULLOSA PIPELINE DETAILS**

- 14.1 Fibrocell Science Inc Business Profile
- 14.2 Fibrocell Science Inc Epidermolysis Bullosa Drug Details
  - 14.2.1 Drug Snapshot
    - 14.2.1.1 Originator
    - 14.2.1.2 Collaborator/Co-Developer
    - 14.2.1.3 Route of Administration
    - 14.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 14.2.1.5 Area
    - 14.2.1.6 Type of Molecular Entity
- 14.3 Current Status
- 14.4 Drug Overview
- 14.5 Drug Mechanism of Action
- 14.6 Clinical/Pre-clinical Trial Details
- 14.7 Latest Drug Developments

## **15. GLAXOSMITHKLINE PLC EPIDERMOLYSIS BULLOSA PIPELINE DETAILS**

- 15.1 GlaxoSmithKline Plc Business Profile
- 15.2 GlaxoSmithKline Plc Epidermolysis Bullosa Drug Details
  - 15.2.1 Drug Snapshot
    - 15.2.1.1 Originator
    - 15.2.1.2 Collaborator/Co-Developer
    - 15.2.1.3 Route of Administration
    - 15.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 15.2.1.5 Area
    - 15.2.1.6 Type of Molecular Entity
- 15.3 Current Status
- 15.4 Drug Overview
- 15.5 Drug Mechanism of Action
- 15.6 Clinical/Pre-clinical Trial Details
- 15.7 Latest Drug Developments

## **16. HOLOSTEM TERAPE AVANZATE SRL EPIDERMOLYSIS BULLOSA PIPELINE DETAILS**

- 16.1 Holostem Terapie Avanzate Srl Business Profile
- 16.2 Holostem Terapie Avanzate Srl Epidermolysis Bullosa Drug Details
  - 16.2.1 Drug Snapshot
    - 16.2.1.1 Originator

- 16.2.1.2 Collaborator/Co-Developer
- 16.2.1.3 Route of Administration
- 16.2.1.4 Orphan Drug/Fast Track/Special Designation
- 16.2.1.5 Area
- 16.2.1.6 Type of Molecular Entity
- 16.3 Current Status
- 16.4 Drug Overview
- 16.5 Drug Mechanism of Action
- 16.6 Clinical/Pre-clinical Trial Details
- 16.7 Latest Drug Developments

## **17. IMMUSOFT CORP EPIDERMOLYSIS BULLOSA PIPELINE DETAILS**

- 17.1 Immusoft Corp Business Profile
- 17.2 Immusoft Corp Epidermolysis Bullosa Drug Details
  - 17.2.1 Drug Snapshot
    - 17.2.1.1 Originator
    - 17.2.1.2 Collaborator/Co-Developer
    - 17.2.1.3 Route of Administration
    - 17.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 17.2.1.5 Area
    - 17.2.1.6 Type of Molecular Entity
- 17.3 Current Status
- 17.4 Drug Overview
- 17.5 Drug Mechanism of Action
- 17.6 Clinical/Pre-clinical Trial Details
- 17.7 Latest Drug Developments

## **18. INMED PHARMACEUTICALS INC EPIDERMOLYSIS BULLOSA PIPELINE DETAILS**

- 18.1 InMed Pharmaceuticals Inc Business Profile
- 18.2 InMed Pharmaceuticals Inc Epidermolysis Bullosa Drug Details
  - 18.2.1 Drug Snapshot
    - 18.2.1.1 Originator
    - 18.2.1.2 Collaborator/Co-Developer
    - 18.2.1.3 Route of Administration
    - 18.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 18.2.1.5 Area

- 18.2.1.6 Type of Molecular Entity
- 18.3 Current Status
- 18.4 Drug Overview
- 18.5 Drug Mechanism of Action
- 18.6 Clinical/Pre-clinical Trial Details
- 18.7 Latest Drug Developments

## **19. KRYSTAL BIOTECH INC EPIDERMOLYSIS BULLOSA PIPELINE DETAILS**

- 19.1 Krystal Biotech Inc Business Profile
- 19.2 Krystal Biotech Inc Epidermolysis Bullosa Drug Details
  - 19.2.1 Drug Snapshot
    - 19.2.1.1 Originator
    - 19.2.1.2 Collaborator/Co-Developer
    - 19.2.1.3 Route of Administration
    - 19.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 19.2.1.5 Area
    - 19.2.1.6 Type of Molecular Entity
- 19.3 Current Status
- 19.4 Drug Overview
- 19.5 Drug Mechanism of Action
- 19.6 Clinical/Pre-clinical Trial Details
- 19.7 Latest Drug Developments

## **20. LIFE SCIENCES INSTITUTE INC EPIDERMOLYSIS BULLOSA PIPELINE DETAILS**

- 20.1 Life Sciences Institute Inc Business Profile
- 20.2 Life Sciences Institute Inc Epidermolysis Bullosa Drug Details
  - 20.2.1 Drug Snapshot
    - 20.2.1.1 Originator
    - 20.2.1.2 Collaborator/Co-Developer
    - 20.2.1.3 Route of Administration
    - 20.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 20.2.1.5 Area
    - 20.2.1.6 Type of Molecular Entity
- 20.3 Current Status
- 20.4 Drug Overview
- 20.5 Drug Mechanism of Action

- 20.6 Clinical/Pre-clinical Trial Details
- 20.7 Latest Drug Developments

## **21. MALLINCKRODT PLC EPIDERMOLYSIS BULLOSA PIPELINE DETAILS**

- 21.1 MallInckrodt Plc Business Profile
- 21.2 MallInckrodt Plc Epidermolysis Bullosa Drug Details
  - 21.2.1 Drug Snapshot
    - 21.2.1.1 Originator
    - 21.2.1.2 Collaborator/Co-Developer
    - 21.2.1.3 Route of Administration
    - 21.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 21.2.1.5 Area
    - 21.2.1.6 Type of Molecular Entity
- 21.3 Current Status
- 21.4 Drug Overview
- 21.5 Drug Mechanism of Action
- 21.6 Clinical/Pre-clinical Trial Details
- 21.7 Latest Drug Developments

## **22. MESOBLAST LTD EPIDERMOLYSIS BULLOSA PIPELINE DETAILS**

- 22.1 Mesoblast Ltd Business Profile
- 22.2 Mesoblast Ltd Epidermolysis Bullosa Drug Details
  - 22.2.1 Drug Snapshot
    - 22.2.1.1 Originator
    - 22.2.1.2 Collaborator/Co-Developer
    - 22.2.1.3 Route of Administration
    - 22.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 22.2.1.5 Area
    - 22.2.1.6 Type of Molecular Entity
- 22.3 Current Status
- 22.4 Drug Overview
- 22.5 Drug Mechanism of Action
- 22.6 Clinical/Pre-clinical Trial Details
- 22.7 Latest Drug Developments

## **23. PALVELLA THERAPEUTICS LLC EPIDERMOLYSIS BULLOSA PIPELINE DETAILS**

- 23.1 Palvella Therapeutics LLC Business Profile
- 23.2 Palvella Therapeutics LLC Epidermolysis Bullosa Drug Details
  - 23.2.1 Drug Snapshot
    - 23.2.1.1 Originator
    - 23.2.1.2 Collaborator/Co-Developer
    - 23.2.1.3 Route of Administration
    - 23.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 23.2.1.5 Area
    - 23.2.1.6 Type of Molecular Entity
- 23.3 Current Status
- 23.4 Drug Overview
- 23.5 Drug Mechanism of Action
- 23.6 Clinical/Pre-clinical Trial Details
- 23.7 Latest Drug Developments

## **24. PHOENIX TISSUE REPAIR INC EPIDERMOLYSIS BULLOSA PIPELINE DETAILS**

- 24.1 Phoenix Tissue Repair Inc Business Profile
- 24.2 Phoenix Tissue Repair Inc Epidermolysis Bullosa Drug Details
  - 24.2.1 Drug Snapshot
    - 24.2.1.1 Originator
    - 24.2.1.2 Collaborator/Co-Developer
    - 24.2.1.3 Route of Administration
    - 24.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 24.2.1.5 Area
    - 24.2.1.6 Type of Molecular Entity
- 24.3 Current Status
- 24.4 Drug Overview
- 24.5 Drug Mechanism of Action
- 24.6 Clinical/Pre-clinical Trial Details
- 24.7 Latest Drug Developments

## **25. PROQR THERAPEUTICS NV EPIDERMOLYSIS BULLOSA PIPELINE DETAILS**

- 25.1 ProQR Therapeutics NV Business Profile
- 25.2 ProQR Therapeutics NV Epidermolysis Bullosa Drug Details
  - 25.2.1 Drug Snapshot

- 25.2.1.1 Originator
- 25.2.1.2 Collaborator/Co-Developer
- 25.2.1.3 Route of Administration
- 25.2.1.4 Orphan Drug/Fast Track/Special Designation
- 25.2.1.5 Area
- 25.2.1.6 Type of Molecular Entity
- 25.3 Current Status
- 25.4 Drug Overview
- 25.5 Drug Mechanism of Action
- 25.6 Clinical/Pre-clinical Trial Details
- 25.7 Latest Drug Developments

## **26. REGENERX BIOPHARMACEUTICALS INC EPIDERMOLYSIS BULLOSA PIPELINE DETAILS**

- 26.1 RegeneRx Biopharmaceuticals Inc Business Profile
- 26.2 RegeneRx Biopharmaceuticals Inc Epidermolysis Bullosa Drug Details
  - 26.2.1 Drug Snapshot
    - 26.2.1.1 Originator
    - 26.2.1.2 Collaborator/Co-Developer
    - 26.2.1.3 Route of Administration
    - 26.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 26.2.1.5 Area
    - 26.2.1.6 Type of Molecular Entity
- 26.3 Current Status
- 26.4 Drug Overview
- 26.5 Drug Mechanism of Action
- 26.6 Clinical/Pre-clinical Trial Details
- 26.7 Latest Drug Developments

## **27. RHEACELL GMBH & CO KG EPIDERMOLYSIS BULLOSA PIPELINE DETAILS**

- 27.1 RHEACELL GmbH & Co KG Business Profile
- 27.2 RHEACELL GmbH & Co KG Epidermolysis Bullosa Drug Details
  - 27.2.1 Drug Snapshot
    - 27.2.1.1 Originator
    - 27.2.1.2 Collaborator/Co-Developer
    - 27.2.1.3 Route of Administration
    - 27.2.1.4 Orphan Drug/Fast Track/Special Designation

- 27.2.1.5 Area
- 27.2.1.6 Type of Molecular Entity
- 27.3 Current Status
- 27.4 Drug Overview
- 27.5 Drug Mechanism of Action
- 27.6 Clinical/Pre-clinical Trial Details
- 27.7 Latest Drug Developments

## **28. SHIONOGI & CO LTD EPIDERMOLYSIS BULLOSA PIPELINE DETAILS**

- 28.1 Shionogi & Co Ltd Business Profile
- 28.2 Shionogi & Co Ltd Epidermolysis Bullosa Drug Details
  - 28.2.1 Drug Snapshot
    - 28.2.1.1 Originator
    - 28.2.1.2 Collaborator/Co-Developer
    - 28.2.1.3 Route of Administration
    - 28.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 28.2.1.5 Area
    - 28.2.1.6 Type of Molecular Entity
- 28.3 Current Status
- 28.4 Drug Overview
- 28.5 Drug Mechanism of Action
- 28.6 Clinical/Pre-clinical Trial Details
- 28.7 Latest Drug Developments

## **29. TWI BIOTECHNOLOGY INC EPIDERMOLYSIS BULLOSA PIPELINE DETAILS**

- 29.1 TWi Biotechnology Inc Business Profile
- 29.2 TWi Biotechnology Inc Epidermolysis Bullosa Drug Details
  - 29.2.1 Drug Snapshot
    - 29.2.1.1 Originator
    - 29.2.1.2 Collaborator/Co-Developer
    - 29.2.1.3 Route of Administration
    - 29.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 29.2.1.5 Area
    - 29.2.1.6 Type of Molecular Entity
- 29.3 Current Status
- 29.4 Drug Overview
- 29.5 Drug Mechanism of Action



29.6 Clinical/Pre-clinical Trial Details  
29.7 Latest Drug Developments

## **20. LATEST EPIDERMOLYSIS BULLOSA DRUG PIPELINE DEVELOPMENTS, 2019**

### **21. APPENDIX**

21.1 About Us  
21.2 Sources and Methodology  
21.3 Contact Information

## I would like to order

Product name: 2019 Future of Epidermolysis Bullosa R&D Pipeline Drugs and Companies- Analysis of Global Epidermolysis Bullosa Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/2D6F96EEE35EN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2D6F96EEE35EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970